How a Breast-Milk-Derived Peptide Could Change Bladder Cancer Care
For people with non-muscle-invasive bladder cancer, treatment can involve repeated procedures, a high risk of tumor recurrence, toxic therap...
Radio and PodcastLive Radio & PodcastsBusiness
The Bio Report
The Bio Report podcast, hosted by veteran journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Episodes
20 of 634 episodesTargeting Visceral Fat with RNA Therapeutics
GLP-1 therapies have dramatically reshaped obesity care, but the next generation of medicines may be judged by more than how much weight pat...
Engineering T-Cell Engagers for Solid Cancers
T-cell engagers have delivered important advances in blood cancers, but extending their success to solid tumors has proved considerably more...
Resetting Severe Allergies at Their Cellular Source
For people with severe allergies and mast cell diseases, the risk of a dangerous reaction can shape everyday decisions about food, activitie...
Innovating ADCs with Dual Targeting and Smarter Delivery
Antibody-drug conjugates have established themselves as an important cancer-treatment modality, but their effectiveness and tolerability in...
Targeting the Brain’s Immune System in Alzheimer’s Disease
Alzheimer’s disease remains one of medicine’s most intractable challenges. While existing therapies may address individual features of the d...
How Gilead Is Building Durable Oncology and Immunology Franchises
Gilead today stands at an inflection point. Its HIV and broader virology business still account for roughly two-thirds of total revenue, eve...
Protecting the Brain After Stroke
Ischemic stroke remains one of the most devastating and resource‑intensive emergencies in medicine, with the physical removal of a clot, the...
Turning the Thymus into an Engine of Immune Tolerance in T1D and Beyond
Type 1 diabetes is still a disease we manage day‑to‑day rather than prevent, and today’s approaches do little to stop the immune system from...
Unlocking Major Targets with Mini Proteins
Most small molecule drugs and biologics miss a large group of important receptors in the body. These receptors, known as GPCRs, play big rol...
Addressing a Data Problem to Enable AI-Drug Discovery
AI’s promise in drug discovery is being held back by a simple but stubborn problem: the field doesn’t have enough of the right kind of lab-g...
Turning Multi Specific Antibody Design into an Engineering Discipline with AI
Multi-specific antibodies promise to unlock complex biology that conventional monoclonals can’t touch, but their added mechanisms of action...
Addressing the Treatment Gap in Ischemic Stroke
Acute ischemic stroke is both ubiquitous and undertreated. Only a small fraction of patients currently receive clot-busting drugs or mechani...
A Pipeline in a Product that Reimagines Control of Inflammation
Plasma gelsolin is an abundant, endogenous regulator of inflammation that is consumed during severe inflammatory insults. When levels fall t...
Building a Genetics Engine to Crack the Target Bottleneck
A chronic shortage of high‑quality targets remains one of the biggest constraints in drug discovery, even as therapeutic tools become more p...
Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug
Epigenetics, the layer of chemical switches that controls how genes are turned on and off, can act like cancer’s operating system when a sin...
Rewriting the Rules of Antibody Drug Design
Most marketed antibodies work as antagonists, simply shutting off a receptor, even though many immune, metabolic, and cancer pathways requir...
Mapping Cellular Stress Biology to Tackle Undruggable Targets
Cells continuously sense their environment and in response to stressors, adapt, recover, or die. Soley Therapeutics uses its AI platform to...
Turning Abandoned Drugs into Breakthroughs
Promising drugs can become abandoned or underused because of tolerability issues, poor drug‑like properties, or other fixable limitations, e...
Targeting Cancer Survival Genes in Solid Tumors
Most cancer therapies hit one or a few pathways that tumors can escape by mutating, activating alternative survival routes, or pumping drugs...